Great Lakes Advisors LLC Sells 1,435 Shares of Bristol-Myers Squibb (NYSE:BMY)
Great Lakes Advisors LLC Sells 1,435 Shares of Bristol-Myers Squibb (NYSE:BMY)
Great Lakes Advisors LLC reduced its holdings in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 28.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,623 shares of the biopharmaceutical company's stock after selling 1,435 shares during the quarter. Great Lakes Advisors LLC's holdings in Bristol-Myers Squibb were worth $265,000 at the end of the most recent quarter.
据百时美施贵宝(纽约证券交易所代码：BMY-GET，评级：BMY-GET)最近向美国证券交易委员会提交的13F文件显示，五大湖顾问公司在第一季度减持了28.4%的百时美施贵宝股票。该基金在本季度出售了1,435股后，持有这家生物制药公司的3623股股票。截至最近一个季度末，五大湖顾问公司在百时美施贵宝持有的股份价值26.5万美元。
A number of other large investors have also recently made changes to their positions in BMY. Mizuho Securities Co. Ltd. grew its position in shares of Bristol-Myers Squibb by 239.0% in the 1st quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 239 shares during the last quarter. Spectrum Management Group LLC grew its position in shares of Bristol-Myers Squibb by 113.1% in the 1st quarter. Spectrum Management Group LLC now owns 341 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 181 shares during the last quarter. Nauset Wealth Management. LLC bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. Conrad Siegel Investment Advisors Inc. bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $28,000. Finally, Steward Financial Group LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $29,000. 73.07% of the stock is currently owned by institutional investors.
其他一些大型投资者最近也改变了他们在BMY的头寸。瑞穗证券第一季度对百时美施贵宝股票的持仓增加了239.0%。瑞穗证券株式会社(Mizuho Securities Co.Ltd.)现在持有这家生物制药公司339股股票，价值25,000美元，上个季度又购买了239股。第一季度，SPECTRUM管理集团对百时美施贵宝股票的持仓增加了113.1%。SPECTRUM Management Group LLC现在持有这家生物制药公司341股股票，价值2.5万美元，上个季度又购买了181股。Nauset财富管理公司。LLC在第一季度购买了价值约2.7万美元的百时美施贵宝(Bristol-Myers Squibb)新股。康拉德·西格尔投资顾问公司(Conrad Siegel Investment Advisors Inc.)在第一季度购买了价值约28,000美元的百时美施贵宝(Bristol-Myers Squibb)股票。最后，Steward Financial Group LLC在第四季度购买了价值约2.9万美元的百时美施贵宝(Bristol-Myers Squibb)股票。73.07%的股票目前由机构投资者持有。
Insider Activity at Bristol-Myers Squibb
百时美施贵宝的内幕活动
In related news, EVP Sandra Leung sold 65,000 shares of the company's stock in a transaction on Monday, June 6th. The stock was sold at an average price of $74.89, for a total transaction of $4,867,850.00. Following the completion of the sale, the executive vice president now owns 308,627 shares in the company, valued at $23,113,076.03. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Giovanni Caforio sold 30,000 shares of the company's stock in a transaction on Monday, June 13th. The stock was sold at an average price of $74.04, for a total transaction of $2,221,200.00. Following the completion of the sale, the chief executive officer now owns 551,104 shares in the company, valued at $40,803,740.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sandra Leung sold 65,000 shares of the business's stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $74.89, for a total value of $4,867,850.00. Following the sale, the executive vice president now directly owns 308,627 shares of the company's stock, valued at approximately $23,113,076.03. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.
在相关新闻中，执行副总裁梁淑仪在6月6日星期一的一笔交易中出售了6.5万股该公司的股票。该股以74.89美元的平均价格出售，总成交金额为4867,850.00美元。出售完成后，执行副总裁总裁现在拥有该公司308,627股股份，价值23,113,076.03美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过这个超链接访问该文件。在相关新闻中，首席执行官乔瓦尼·卡福里奥在6月13日(星期一)的一次交易中出售了30,000股公司股票。该股以74.04美元的平均价格出售，总成交金额为2221,200.00美元。出售完成后，首席执行官目前拥有该公司551,104股，价值40,803,740.16美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过这个超链接访问该文件。此外，执行副总裁梁淑仪在6月6日星期一的交易中出售了6.5万股该公司的股票。这些股票的平均价格为74.89美元，总价值为4,867,850.00美元。出售后，执行副总裁总裁现在直接持有该公司308,627股股票，价值约23,113,076.03美元。此次拍卖的披露信息可在此处找到。0.09%的股份由公司内部人士持有。
Bristol-Myers Squibb Stock Up 1.6 %
百时美施贵宝股价上涨1.6%
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last posted its quarterly earnings results on Wednesday, July 27th. The biopharmaceutical company reported $1.93 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.14. Bristol-Myers Squibb had a return on equity of 49.31% and a net margin of 14.04%. The firm had revenue of $11.89 billion during the quarter, compared to analysts' expectations of $11.50 billion. During the same quarter in the previous year, the business earned $1.93 earnings per share. The company's revenue was up 1.6% on a year-over-year basis. Equities analysts forecast that Bristol-Myers Squibb will post 7.53 earnings per share for the current fiscal year.
百时美施贵宝(纽约证券交易所代码：BMY-GET Rating)最近一次公布季度收益是在7月27日星期三。这家生物制药公司公布本季度每股收益为1.93美元，比普遍预期的1.79美元高出0.14美元。百时美施贵宝的股本回报率为49.31%，净利润率为14.04%。该公司本季度营收为118.9亿美元，高于分析师预期的115亿美元。去年同期，该业务每股收益为1.93美元。该公司的收入同比增长了1.6%。股票分析师预测，百时美施贵宝本财年每股收益将达到7.53欧元。
Bristol-Myers Squibb Dividend Announcement
百时美施贵宝宣布派息
The company also recently disclosed a quarterly dividend, which was paid on Monday, August 1st. Investors of record on Friday, July 1st were given a dividend of $0.54 per share. This represents a $2.16 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date was Thursday, June 30th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 71.76%.
该公司最近还披露了季度股息，股息于8月1日(星期一)支付。7月1日(星期五)登记在册的投资者获得了每股0.54美元的股息。这意味着年化股息为2.16美元，收益率为2.88%。除息日期为6月30日星期四。百时美施贵宝的股息支付率(DPR)目前为71.76%。
Analyst Ratings Changes
分析师评级发生变化
BMY has been the topic of several research reports. Truist Financial lifted their price target on Bristol-Myers Squibb from $76.00 to $81.00 in a research report on Monday, May 2nd. Atlantic Securities lifted their price target on Bristol-Myers Squibb from $82.00 to $83.00 and gave the company an "overweight" rating in a research report on Thursday, July 28th. Raymond James lowered Bristol-Myers Squibb from an "outperform" rating to a "market perform" rating in a research report on Friday, June 3rd. They noted that the move was a valuation call. BMO Capital Markets lifted their price target on Bristol-Myers Squibb from $87.00 to $92.00 in a research report on Monday, May 2nd. Finally, JPMorgan Chase & Co. lifted their price target on Bristol-Myers Squibb from $80.00 to $85.00 in a research report on Thursday, July 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $75.57.
BMY一直是几份研究报告的主题。在5月2日周一的一份研究报告中，Truist Financial将百时美施贵宝的目标价从76.00美元上调至81.00美元。大西洋证券在7月28日周四的一份研究报告中将百时美施贵宝的目标价从82.00美元上调至83.00美元，并给予该公司“增持”评级。雷蒙德·詹姆斯在6月3日(星期五)的一份研究报告中将百时美施贵宝的评级从“跑赢大盘”下调至“市场表现”。他们指出，此举是一次估值预测。蒙特利尔银行资本市场在5月2日周一的一份研究报告中将百时美施贵宝的目标价从87.00美元上调至92.00美元。最后，摩根大通在7月28日星期四的一份研究报告中将百时美施贵宝的目标价从80.00美元上调至85.00美元。一名投资分析师对该股的评级为卖出，四名分析师发布了持有评级，七名分析师发布了买入评级，一名分析师对该公司股票发布了强烈的买入评级。根据MarketBeat.com的数据，该公司目前的平均评级为“中等买入”，平均目标价为75.57美元。
About Bristol-Myers Squibb
关于百时美施贵宝
(Get Rating)
(获取评级)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
百时美施贵宝公司在全球发现、开发、许可、制造和营销生物制药产品。它提供血液学、肿瘤学、心血管学、免疫学、纤维化、神经科学和新冠肺炎疾病的产品。该公司的产品包括治疗多发性骨髓瘤的口服免疫调节药物Revlimid；用于降低NVAF中风/系统性栓塞风险和治疗DVT/PE的口服抑制剂Eiquis；用于抗癌适应症的Opdivo；用于多发性骨髓瘤患者的Pomalyst/Imnovid；以及用于成人活动期RA和牛皮癣关节炎的Orencia。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- CVS and Walgreens Show Why Investment Objectives Matter
- This Defense Stock Has Bullish Fundamentals AND Technicals
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
- 免费获取StockNews.com关于百时美施贵宝(BMY)的研究报告
- 3M、霍尼韦尔、通用电气在季度报告后收购吗？
- 索菲金融股票终于准备好为投资者买单了吗？
- CVS和Walgreens展示为什么投资目标很重要
- 这只国防股票的基本面和技术面都看涨
- 美敦力和直觉外科公司准备实现大增长吗？
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
接受百时美施贵宝日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对百时美施贵宝及相关公司评级的每日摘要。
译文内容由第三方软件翻译。